3 Chapter 1 Our Vision

- 22 Chapter 2 Sustainable Growth Strategy
- 56 Chapter 3 Strengthening ESG Activities
- 95 Chapter 4 Financial/Non-Financial Information
- 96 11-Year Financial Summary
- 97 Financial/Non-Financial Highlights
- 101 Overview of Business Domains | Summary

-103 Overview of Business Domains | Results by Segment

- 105 Shareholder Information
- 106 Consolidated Financial Statements
- 112 Non-Financial Information • Environmental Data/Social Data • Independent Assurance Report





Overview of Business Domains | Results by Segment (1)

Performance Products segment

Sales revenue amounted to ¥1,252.7 billion, a year-on-year increase of ¥116.4 billion, and core operating income to ¥51.5 billion, a decrease of ¥27.2 billion.

Sales revenue in the Polymers & Compounds subsegment increased despite the fall in sales volume in automotive applications in particular. The growth was due mainly to active passing on of rising raw material costs to sales prices and currency translation effects.

Sales revenue in the Films & Molding Materials subsegment increased due notably to sales price corrections reflecting raw material price rises and currency translation effects, which largely absorbed the impact of the previous fiscal year's transfer of the alumina fiber business and the sharp fall in demand in display applications. Sales revenue in the Advanced Solutions subsegment increased due mainly to sales prices corrections to reflect raw material price rises and currency translation effects, which absorbed the impact of a decrease in sales volume mainly in display applications.

Core operating income decreased due to the general decline in demand, particularly in display applications, and the inflation-driven increase in costs, only partly balanced by active passing on of costs to sales prices to reflect raw material price rises.

Performance Products: Factors underlying the YoY change in core operating income (Billions of yen)



* Includes differences due to gains/losses on inventory valuation and to gains/ losses on equity-method investments **Polymers & Compounds**

Develops greater added value for various materials and delivers highperformance materials to the world • Performance polymers • Polycarbonate

s highworld

Coating material ACRYKING

Films & Molding Materials

Coating materials, etc.

Utilizes a range of molding technologies to provide products designed for different applications • Packaging (food packaging) and industrial films • Polyester films

High-performance engineering plastics
 Food packs
 Carbon fiber and composite materials, etc.

Advanced Solutions

Offers new solutions to society's search for value, through advanced products and technologies, business models, and ideas

Aqua solutions
Life solutions
Semiconductors & electronics
Battery materials, etc.



Semiconductor-related materials

Chapter

Chapter

Industrial Materials Domain



Chemicals segment

Sales revenue amounted to ¥1,430.2 billion, a year-on-year increase of ¥142.3 billion, and core operating income to ¥9.2 billion, a decrease of ¥93 billion.

Sales revenue in the MMA subsegment decreased despite the positive effect particularly of currency translation, as sales volume decreased due to decline in demand and sales prices fell for MMA monomers and other products.

Sales revenue in the Petrochemicals subsegment increased due to sales price increases mainly reflecting rising raw material prices. This growth outweighed the decrease in sales volume due to declining demand and the increased impact of scheduled maintenance and repair at our ethylene production facilities.

Sales revenue in the Carbon Products subsegment grew on rising sales prices due to an increase in the sale price of coke, in turn driven mainly by rising raw material prices, which outweighed the decreased sales volume resulting from declining demand.

Core operating income decreased due mainly to the decreased sales volume resulting from declining demand combined with the

general narrowing of the price margin between raw material and finished product and a decrease in inventory valuation gain.

Chemicals: Factors underlying the YoY change in core operating income (Billions of yen)



Includes differences due to gains/losses on inventory valuation and to gains/ losses on equity-method investments Chapter

È.

3 Chapter 1 Our Vision

- 22 Chapter 2 Sustainable Growth Strategy
- 56 Chapter 3 Strengthening ESG Activities
- 95 Chapter 4 Financial/Non-Financial Information
- 96 11-Year Financial Summary
- 97 Financial/Non-Financial Highlights
- 101 Overview of Business Domains Summarv

-103 Overview of Business Domains **Results by Segment**

- 105 Shareholder Information
- 106 Consolidated Financial Statements
- 112 Non-Financial Information Environmental Data/Social Data Independent Assurance Report

Overview of Business Domains | Results by Segment (2)

Industrial Gases segment Sales revenue amounted to ¥1,177.9 billion, a year-on-year increase

of ¥227.8 billion, and core operating income to ¥121.0 billion, an increase of ¥22.1 billion.

Sales revenue and core operating income increased due to sales volumes being boosted by robust demand in the domestic and overseas markets. Higher sales prices driven by fuel price rises and currency translation effects also contributed.

Industrial Gases: Factors underlying the YoY change in core operating income (Billions of yen)



MMA

Manufactures MMA using all three of the main manufacturing methods and delivers global supplies of MMA and MMA derivative acrylic resin • MMA • PMMA



PMMA acrylic resin block

Carbon Products business

Uses superior coking coal formulation and quality control technologies to deliver stable supplies in Japan and overseas



•Coke •Carbon black

Carbon materials

Synthetic rubbers

Industrial Gases business

Commands a top share of the domestic market and has built a global supply system with sites in Japan, the United States, Europe, and Asia



Industrial gases business

Chapter

Chapter

Chapter

15 (Revenue from Contracts with Customers). However, as the arbitration court judged all the provisions of the relevant contract to be valid in February 2023, sales revenue of ¥125.9 billion was recognized in the consolidated accounting period of the fourth guarter of fiscal 2022.

Pharma business

(FY)

Develops precision medicine and around the pill solutions in fields where there are unmet medical needs

 Central nervous system Immuno-inflammation • Diabetes and kidney Oncology



Biopharmaceuticals

Health Care: Factors underlying the YoY change in core operating income (loss) (Billions of yen) 160 125.9 120 80 40 17.1



pharmaceuticals market. The factors in the increase included

robust sales of priority products in the Japanese market and of

(ALS) released in the United States in June 2022, together with

royalty revenue* from Gilenya, a treatment agent for multiple

RADICAVA ORS, a treatment agent for amyotrophic lateral sclerosis



S Return to the previously viewed page

sclerosis outlicensed to Novartis Pharma AG.





Health Care Domain



Health Care segment

Sales revenue amounted to ¥547.1 billion, a vear-on-vear increase of ¥143.5 billion, and core operating income to ¥141.8 billion, an increase of ¥148.8 billion.

Sales revenue and core operating income in this segment increased despite the impact of negative factors including National Health Insurance drug price revisions in the Japanese ethical

Petrochemicals business

chemical derivatives

Polvolefins

Operates ethylene plants in Japan and delivers stable supplies of petrochemical materials as well as high-performance polyolefins

Industrial gases



